Product

Pancrelipase

Aliases

ABT-SLV-245, Creon

Name

Creon

INN Name

Pancrelipase

FDA Approved

Yes

4 clinical trials

1 organization

4 indications

1 document

Indication

Exocrine Pancreatic Insufficiency

Indication

Cystic Fibrosis

Indication

Pancreatic adenocarcinoma

Indication

pancreatic insufficiency

Clinical trial

Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects

Status: Terminated, Estimated PCD: 2022-03-23

Clinical trial

A Phase 4 Study to Compare US Marketed Creon Drug Product With Drug Product Manufactured With a Modernized Process at an Alternate Manufacturing Site and With Drug Product Manufactured With the Approved Manufacturing Process at an Alternate Active Pharmaceutical Ingredient Site, in Subjects With EPI Due to Cystic Fibrosis

Status: Completed, Estimated PCD: 2022-07-11

Clinical trial

Pancreatic-enzyme Replacement Therapy With Pancreaze (Pancrelipase) Delayed-release in Addition to Standard of Care for Borderline Resectable, Locally Advanced, and Advanced Pancreatic Adenocarcinoma Patients (PANCAX-3) With Cachexia and Exocrine Pancreatic Insufficiency

Status: Recruiting, Estimated PCD: 2023-12-01

Clinical trial

Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic Insufficiency: the PERT-AP Trial

Status: Recruiting, Estimated PCD: 2026-12-31

Document

DailyMed Label: Creon

Organization